Anika Therapeutics, Inc. ANIK
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.76% | 80.50% | 80.70% | 66.12% | 18.27% |
| Total Depreciation and Amortization | -13.08% | -25.81% | -27.93% | -42.37% | -42.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.60% | -65.84% | -74.22% | -65.39% | -21.46% |
| Change in Net Operating Assets | -203.56% | -6.09% | 93.71% | 84.60% | 56.35% |
| Cash from Operations | -4.81% | 19.87% | 107.07% | 9.04% | -29.67% |
| Capital Expenditure | 20.53% | 37.91% | 11.74% | 9.46% | 12.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | 0.00% | -- | -- | -- |
| Other Investing Activities | 132.68% | -295.83% | -327.83% | -468.83% | -- |
| Cash from Investing | -103.67% | 31.77% | 95.19% | 78.50% | 74.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -19.53% | -34.30% | -36.22% | -32.69% | -32.69% |
| Repurchase of Common Stock | -10.73% | 4.17% | 18.22% | -42.25% | -280.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.89% | 2.73% | 17.11% | -51.09% | -363.32% |
| Foreign Exchange rate Adjustments | -151.36% | -156.04% | 279.17% | -86.71% | 383.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.82% | 19.05% | 102.05% | 47.14% | -329.30% |